DEXAMETHASONE IMPLANT AND AFLIBERCEPT COMBINATION THERAPY VERSUS AFLIBERCEPT MONOTHERAPY FOR DIABETIC MACULAR EDEMA: A Prospective, Comparative Trial (COED Trial).
RetinaSep 1, 2026
Clinical ResearchOphthalmology
Irene Park Kim, Christine Orndahl, Caroline Nyaiburi et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial compared the efficacy of combined dexamethasone implant and intravitreal aflibercept (AFB) versus AFB monotherapy in 50 patients with diabetic macular edema (DME). The combination therapy resulted in quicker resolution of DME, with a median difference of 12 weeks, although it did not significantly improve visual acuity or central subfield retinal thickness compared to AFB alone.
Key findings
- Combined therapy led to a quicker resolution of DME by a median of 12 weeks.
- No significant difference in best-corrected visual acuity change between groups (P = 0.266).
- Injection frequency was numerically lower in the combination group (4.9 vs 5.9).
- Higher incidence of cataracts and intraocular pressure elevation in the combined therapy group.
Why it matters
Understanding the comparative effectiveness and safety of combination therapies for DME is crucial for optimizing treatment strategies and managing potential complications in patients.